SCHEMBL23917563

SCHEMBL23917563

C=CC(=O)Oc1cc(F)cc(-c2nn(C)c3ncnc(N)c23)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 10/20 0.55
FGFR2 P21802 9/20 0.55
FGFR3 P22607 9/20 0.55
PIK3CD O00329 8/20 0.50
FGFR4 P22455 8/20 0.50
PIK3CA P42336 7/20 0.50
PIK3CB P42338 7/20 0.50
PIK3CG P48736 7/20 0.50
PRKDC P78527 7/20 0.50
ABL1 P00519 6/20 0.50
EGFR P00533 6/20 0.50
HCK P08631 6/20 0.50
SRC P12931 6/20 0.50
MTOR P42345 6/20 0.50
EPHB4 P54760 6/20 0.50
KDR P35968 5/20 0.50
PI4KB Q9UBF8 3/20 0.47
NUDT14 O95848 1/20 0.47
NUDT5 Q9UKK9 1/20 0.47
BTK Q06187 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130486 0.82 PIK3CD (0.63) FGFR1FGFR2FGFR3PIK3CDPIK3CA
SCHEMBL23917564 0.78 FGFR1 (0.43) FGFR1FGFR2FGFR3PIK3CDFGFR4
SCHEMBL129487 0.78 PIK3CD (0.72) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL16655467 0.77 PIK3CD (0.75) PIK3CDEGFRBTK
SCHEMBL18874137 0.75 PIK3CD (0.53) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL129505 0.74 PIK3CD (0.62) FGFR1FGFR2FGFR3PIK3CDFGFR4
SCHEMBL23917472 0.73 SRC (0.52) FGFR1FGFR2FGFR3PIK3CDFGFR4
SCHEMBL129595 0.73 PIK3CD (0.62) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL18874138 0.72 PIK3CD (0.55) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL16701712 0.72 PIK3CD (0.59) FGFR1FGFR2FGFR3PIK3CDFGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317140-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317140-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB FGFR1 2569/4885FGFR2 1759/4885FGFR3 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.